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A B S T R A C T
Babesiosis is a tick-transmitted zoonosis caused by apicomplexan parasites of the genus Babesia. Treatment of
this emerging malaria-related disease has relied on antimalarial drugs and antibiotics. The proteasome of
Plasmodium, the causative agent of malaria, has recently been validated as a target for anti-malarial drug de-
velopment and therefore, in this study, we investigated the effect of epoxyketone (carfilzomib, ONX-0914 and
epoxomicin) and boronic acid (bortezomib and ixazomib) proteasome inhibitors on the growth and survival of
Babesia. Testing the compounds against Babesia divergens ex vivo revealed suppressive effects on parasite growth
with activity that was higher than the cytotoxic effects on a non-transformed mouse macrophage cell line.
Furthermore, we showed that the most-effective compound, carfilzomib, significantly reduces parasite multi-
plication in a Babesia microti infected mouse model without noticeable adverse effects. In addition, treatment
with carfilzomib lead to an ex vivo and in vivo decrease in proteasome activity and accumulation of poly-
ubiquitinated proteins compared to untreated control. Overall, our results demonstrate that the Babesia pro-
teasome is a valid target for drug development and warrants the design of potent and selective B. divergens
proteasome inhibitors for the treatment of babesiosis.
1. Introduction
Babesiosis is a malaria-related infection caused by the apicomplexan
intracellular blood parasites of the genus Babesia, that are transmitted
to their vertebrate hosts by the bite of ixodid ticks (Lantos and Krause,
2002). Despite routine epidemiologic surveillance babesiosis has long
been recognized as an economically important disease of livestock
(Zintl et al., 2003; Bock et al., 2004; Gohil et al., 2013), with growing
incidence in both domesticated and wildlife animals (Schnittger et al.,
2012; Gohil et al., 2013; Vannier et al., 2015). Only in the last 40 years
has Babesia been recognized as an important human infection acquired
naturally from interactions with established zoonotic cycles (zoonosis)
(Yabsley and Shock, 2013; Vannier et al., 2015). Besides the natural
infection by tick bites, humans are infected with Babesia also via blood
transfusion with infected blood, or even congenitally during pregnancy
(Ord and Lobo, 2015). The majority of human infections are reported in
the United States (Vannier and Krause, 2012) where the principal agent
of human babesiosis – B. microti – is one of the most common transfu-
sion-transmitted pathogens (Leiby, 2011; Lobo et al., 2013; Yabsley and
Shock, 2013; Vannier et al., 2015). In Europe, most reported medical
cases of babesiosis have been attributed to B. divergens (Uhnoo et al.,
1992; Haapasalo et al., 2010; Hildebrandt et al., 2013; Mørch et al.,
2015).
A number of factors have contributed to the “emergence” of human
babesiosis leading the US Centers for Disease Control and Prevention
(CDC) to add babesiosis to the list of nationally notifiable conditions in
2011. The pathology in humans is a direct result of the parasite's ability
to first recognize and then invade host red blood cells and ranges from
clinically silent infections to intense malaria-like episodes resulting
occasionally in death. Although many infections remain asymptomatic
the burden of severe pathology resides within older or im-
munocompromised patients (Rosner et al., 1984; Benezra et al., 1987;
Falagas and Klempner, 1996; Froberg et al., 2004; Häselbarth et al.,
2007; Stowell et al., 2007; Krause et al., 2008) and is fatal in ap-
proximately 20% of cases where infection was acquired through blood
transfusion (Vannier et al., 2015). This makes transfusion-transmitted
babesiosis an emerging threat to public health as asymptomatic carriers
donate blood, and there are as yet no licensed or regulated tests to
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screen blood products for this pathogen (Yabsley and Shock, 2013;
Vannier et al., 2015). Reports of tick-borne cases within new geo-
graphical regions as well as identifications of new Babesia spp. as agents
of severe human babesiosis suggest rapid changes in epidemiology of
this disease making it a serious public health concern that requires
novel intervention strategies (Leiby, 2011; Lobo et al., 2013; Yabsley
and Shock, 2013; Vannier et al., 2015).
Babesiosis is generally treated using a combination of antimalarial
drugs and antibiotics such as atovaquone and azithromycin (Vannier
et al., 2015). However, the toxic effects of these treatments combined
with an increase in parasite resistance (Wormser et al., 2010; Simon
et al., 2017) and in numbers of relapsed immunocompromised and
asplenic individuals (Lemieux et al., 2016), have made this widely used
anti-babesial treatment regime less effective (Simon et al., 2017).
Therefore, discovery of new drug targets and development of new and
effective antibabesial drugs is urgently needed.
Proteasomes are large multi-component protein complexes that are
constitutively expressed in all living cells and are involved in regulation
of many cellular processes (Adams, 2004). The principal function of the
constitutive proteasomes is to degrade poly-ubiquitinated proteins in
the cytosol and nucleus via the ubiquitin-proteasome system (Voges
et al., 1999; Bedford et al., 2010). A specialized form of the mammalian
constitutive proteasome is the immunoproteasome with higher level of
expression in antigen-presenting cells upon oxidative stress and cyto-
kine stimulation (Ferrington and Gregerson, 2012). Proteasomes are
composed of a barrel-shaped 20S core flanked by the 19S regulatory
units on both ends (Voges et al., 1999; Bedford et al., 2010; Kish-Trier
and Hill, 2013; Tomko and Hochstrasser, 2013). The function of the 19S
subunits is substrate recognition, deubiquitinating, unfolding and
translocation to the proteasome core for degradation (Voges et al.,
1999; Tomko and Hochstrasser, 2013). The 20S core, the site of protein
degradation, is formed by the two rings of α subunits surrounding the
two stacked rings of seven β subunits. In the constitutive proteasome,
three subunits on each of the β rings are proteolytically active with each
subunit having a unique substrate cleavage preference. The β1 subunit
preferentially cleaves on the C-terminal side of acidic residues. Fluor-
escent substrates that were originally developed for mammalian cas-
pases are generally hydrolysed by this subunit. Therefore, the β1 sub-
unit is often referred to as having “caspase-like” activity. In a similar
manner, the β2 subunit cleaves on the C-terminal side of basic residues
and has “trypsin-like” activity, while the β5 has “chymotrypsin-like”
activity as it cleaves after non-polar residues (Verdoes et al., 2006; Kish-
Trier and Hill, 2013). In the mammalian immunoproteasome, the
chymotrypsin-like, trypsin-like and caspase-like proteolytic activities
are performed by the β5, β2 and β1 subunit respective analogues LMP7,
MECL1, and LMP2 (Ferrington and Gregerson, 2012).
Targeting the chymotrypsin-like activity of mammalian proteasome
has been previously verified as a powerful strategy for anti-cancer
therapy. Three proteasome inhibitors targeting the β5 subunit of
mammalian proteasomes and have been approved for treatment of
multiple myeloma (Kane et al., 2003, 2006; Groll et al., 2006;
Kupperman et al., 2010; Kim and Crews, 2013; Bibo-Verdugo et al.,
2017). These include the peptide epoxyketone carfilzomib and two
peptide boronic acid derivatives, bortezomib and ixazomib. In addition,
ONX-0914 selectively targets the chymotrypsin-like immunoprotea-
some subunit LMP7 and controls a pathogenic immune response in
autoimmune disorders (Muchamuel et al., 2009). A recent revolution in
the field of parasitology has been the development of proteasome in-
hibitors that selectively target parasitic organisms but with greatly re-
duced toxicity to the mammalian host (Bibo-Verdugo et al., 2017). Such
selective inhibition may become a powerful strategy to combat infec-
tions such as malaria, leishmaniasis, sleeping sickness, and Chagas
disease (Khare et al., 2016; Li et al., 2016b; LaMonte et al., 2017). In
addition, the synergistic effect of proteasome inhibitors and artemisinin
for the treatment of drug resistant Plasmodium has provided a potential
new strategy for treating malaria (Dogovski et al., 2015; Li et al.,
2016b; LaMonte et al., 2017).
Multi-gene analyses of apicomplexan parasites have positioned
Babesia species as close relatives of Plasmodium species (Burki et al.,
2009; Janouskovec et al., 2010; Arisue and Hashimoto, 2015; Schreeg
et al., 2016) and therefore we predict that selective inhibition of the
Babesia proteasome will represent a novel strategy for the treatment of
babesiosis. In this study, we investigated the effect of proteasome in-
hibitors on B. divergens and B. microti, the causative agents of human
babesiosis, with the goal of validating this target for future drug de-
velopment efforts.
2. Materials and methods
2.1. Parasites
B. divergens 2210A G2 was cultivated in a bovine erythrocyte sus-
pension obtained from a parasite-free cow (culture tested) by a pre-
viously described procedure (Malandrin et al., 2004). Parasites were
cultivated in RPMI 1640 medium (Lonza, Switzerland; cat. no. BE12-
115F) supplemented with 50 μg/ml gentamicin, 0.25 μg/ml amphoter-
icin B and 20% heat-inactivated fetal calf serum (Lonza, Switzerland,
inactivation at 56 °C for 30min before use). B. microti (Franca) Reich-
enow (ATTC® PRA-99™, USA), was maintained by continuous passages
in BALB/c female mice (Charles River Laboratories, Germany) and used
for in vivo experiments. All animals were treated in accordance with the
Animal Protection Law of the Czech Republic no. 246/1992 Sb., ethics
approval No. 112/2016 and all in vivo experiments were approved by
the institutional ethics committee.
2.2. Proteasome inhibitors
Carfilzomib (PR-171), bortezomib (PS-341), epoxomicin, ONX-0914
and ixazomib (MLN9708) were purchased from Selleckchem (USA) and
dissolved to 5mM in DMSO (dimethyl sulfoxide, Sigma-Aldrich, USA).
For treatment of B. divergens cultures, inhibitors were diluted in culture
medium. For treatment of B. microti infected mice, carfilzomib was
diluted in sterile PBS (phosphate buffered saline).
2.3. Treatment of B. divergens ex vivo cultures
To evaluate the effect of proteasome inhibitors on B. divergens
growth and determine their IC50 values, cultures containing 2% para-
sitemia were subsequently cultivated in media with proteasome in-
hibitor concentrations ranging from 6.25 nM to 400 nM. Assays were
performed in triplicate wells in a 96-well plate format and media
containing inhibitors were replaced at 12 h intervals. DMSO diluted in
media served as a vehicle control. After 48 h of incubation, parasite
replication was quantified as the number of infected red blood cells
(RBCs) per 1000 RBCs on thin blood smears stained by Diff-Quik
(Siemens, Germany) (Fig. 1); biological replicates are represented by
three independent wells (RBC cultures) while technical replicates are
represented by three different thin blood smears of each well (RBC
culture) that the parasitemia was counted from. This whole inhibitor
treatment assay was performed twice: firstly as a pilot experiment
(Supplemetary Fig. 1) and than repeated with fresh 2% parasitemia B.
divergens RBC cultures in order to determine IC50 values (Figs. 2 and 3).
2.4. Cell toxicity assay
PMJ2R mouse macrophages (ATCC® CRL2458™, USA) were culti-
vated in RPMI 1640 medium (Lonza, Switzerland; cat. no. BE12-115F)
supplemented with 50 μg/ml gentamicin, 0.25 μg/ml amphotericin B
and 10% heat-inactivated fetal calf serum. HeLa human epithelial cells
(ATCC CCL-2) were grown in DMEM medium with 10% fetal calf
serum. For cytotoxicity assays, compounds were serially diluted, and
added to the mammalian cell cultures in 96-well plates. Vehicle alone
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was used as a control. After 48 h cultivation (37 °C, 5% CO2) cell via-
bility was determined. Viability of HeLa cells was determined using
AlamarBlue reagent (Invitrogen, USA) and replicate assays were per-
formed on three separate days. PMJ2R cells (triplicated cultures) were
stained with the Viability/Cytotoxicity Assay Kit for Animal Live &
Dead Cells (Biotium, USA) following the protocol provided by the
manufacturer. Live cells stained by Calcein AM and dead cells stained
with ethidium homodimer III were quantified by flow cytometry (BD
FACSCanto II, BD Biosciences, USA) in BD FACSDiva software.
2.5. Lysate preparation
B. divergens infected RBCs (∼15% parasitemia) were lysed with
0.15% saponin (Sigma-Aldrich, USA) and asynchronous parasites were
isolated following extensive washing and centrifugation cycles with
PBS. Pelleted parasites were supplemented with 20% glycerol and
stored at−80 °C for further analysis. Parasites (∼50 μl) were added to
500 μl hypotonic lysis buffer (20mM HEPES pH 8.0, 1 μM E64, 0.03%
SDS and 1mM ATP; all Sigma-Aldrich, USA) and ruptured by ultra-
sonication with amplitude 0.5 for 3× 15s (Ultrasonic processor
UP200S, Hielscher, Germany). The resulting crude lysate, originating
from the pool of 10 separate B. divergens cultures, was used for activity
assays.
Fig. 1. Treatment of B. divergens ex vivo cultures: red blood cells infection.
(A) Microscopy image of B. divergens ex vivo culture treated with 100 nM car-
filzomib. (B) Microscopy image of B. divergens ex vivo culture treated with
0.008% DMSO. Smears were stained using DiffQuik staining set. Experimental
conditions: starting parasitemia 2%, medium changed in 12 h intervals, total
cultivation 48 h. Green dots indicate the parasitized red blood cells. (For in-
terpretation of the references to color in this figure legend, the reader is referred
to the Web version of this article.)
Fig. 2. Treatment of B. divergens ex vivo
cultures with peptide epoxyketone in-
hibitors. Structure and IC50 determination
of (A) carfilzomib, (B) epoxomicin, (C)
ONX-0914. Data represent means of three
independent biological replicates and the
error bars indicate standard deviations.
Smears were stained using DiffQuik staining
set, parasitemia was counted at 1000 RBCs.
Statistical analysis was performed in R
using ANOVA (Kolmogorov-Smirnov test
and the Bartlett test passed): * = p < 0.05,
*** = p < 0.001 (compared to the DMSO
treated culture). Experimental conditions:
starting parasitemia 2% (dotted line),
medium with inhibitory compounds ex-
changed in 12 h intervals, total cultivation
duration 48 h. DC: DMSO treated culture
(0.008%). UC: untreated culture. IC50: half
maximal inhibitory concentration. RBCs:
red blood cells.
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2.6. Activity assays
Activity was measured in assays with the 20S proteasome chymo-
trypsin-specific substrate, Suc- LLVY-AMC (Bachem, Switzerland).
Assays were performed in flat-bottom black 96-well plates (CoStar,
USA) using 10 μl of B. divergens lysate per well in the reaction mixture
of 20mM HEPES (pH 8), 1 μM E64, 0.03% SDS, 1mM ATP and 10 μM
Suc-LLVY-AMC. Enzyme kinetics was monitored by Infinite M200 PRO
reader (Tecan, Austria) as increasing fluorescence intensity at 360/
465 nm excitation/emission wavelengths in 1min intervals for 1 h at
37 °C. For specificity control, the parasite lysates were pre-incubated
(30min, 37 °C) with 1 μM concentration of all compounds in the assay
buffer prior the addition of Suc-LLVY-AMC and kinetic assay mea-
surements. To determine IC50 values of all tested inhibitors, the com-
pounds were serially diluted and pre-incubated with parasite lysates
prior the kinetic assay described above. All experiments were per-
formed in triplicate with a single parasite lysate. Results were con-
firmed with repeated experiments using independently prepared B. di-
vergens lysates.
2.7. Western blot analysis of poly-ubiquitinated proteins
Reducing SDS PAGE and Western blot analyses were performed as
described previously (Perner et al., 2016). Briefly, B. divergens lysates
were analysed by SDS-PAGE using the NuPAGE 4–12% Bis-Tris Protein
Gels and visualization by Coomassie Brilliant Blue staining (Thermo-
fisher). For Western blot the unstained SDS PAGE gel loads were electro
blotted to a PVDF (polyvinylidene difluoride) membrane using the
Trans-Blot Turbo system (BioRad, USA). The membrane was blocked in
3% (w/v) non-fat skimmed milk in 1×PBS with 0.05% Tween 20
(PBS-T; Sigma-Aldrich, USA). For immunostaining the membrane was
first exposed to Anti-Ubiquitin K48 Linkage antibodies (Boston Bio-
chem, USA) diluted by 1:2000 in PBS-T, washed (3× 5min) in PBS-T,
and subsequently exposed to the goat anti-rabbit IgG-peroxidase sec-
ondary antibody (Sigma) diluted by 1: 2000 in PBS-T. After the final
wash (4× 5min in PBS-T) the membrane was developed using the
ClarityWestern ECL substrate (BioRad, USA), visualized in the
ChemiDoc MP imager and analysed using Image Lab Software (BioRad,
USA).
2.8. Treatment of B. microti infected mice
Six female BALB/c mice (∼20 g each) were intra-peritoneally in-
jected with 150 μl of B. microti infected blood (50% parasitemia,
∼800×106 of infected red blood cells) obtained from a previously
infected mouse. Starting on the first day post infection (DPI), mice were
treated daily with either 0.75mg/kg of carfilzomib in PBS (three mice)
or a vehicle control (three mice) by intra-peritoneal injection of 150 μl
target or control treatment volume per mouse. Treatment continued for
7 DPI and the health status of the mice was assessed by observation of
activities and physical appearances. Parasite load was monitored daily
for 15 DPI on thin blood smears as described above; blood for ex-
amination was obtained by tail snip.
2.9. Pre-treatment of B. microti infected red blood cells
Three mice with B. microti infection (50% parasitemia) were bled
out and pooled infected blood was treated either with Carfilzomib (final
concentration 400 nM) or with DMSO in appropriate concentration for
1 h at 37 °C and 5% CO2. Treated blood samples were then intra-peri-
toneally injected into three experimental and three control BALB/c
mice (dose volume 150 μl, 800×106 of infected red blood cells).
Parasitemia was monitored daily for 8 DPI on thin blood smears as
described above.
2.10. Activity assay and western blot analysis of poly-ubiquitinated proteins
in B. microti infected mice
To evaluate the in vivo on target effect of carfilzomib, eight female
BALB/c were intra-peritoneally infected with B. microti as described
above. Mice were then treated with either 0.75mg/kg of carfilzomib in
PBS (four mice) or a vehicle control (four mice) on 5 and 6 DPI. On 7
DPI, the blood was collected, and the proteasome activity was analysed
on crude cell lysates prepared from pooled blood taken from treated/
Fig. 3. Treatment of B. divergens ex vivo
cultures with peptide boronic acid in-
hibitors. Structure and IC50 determination
of (A) bortezomib and (B) ixazomib. Results
represent means of three independent bio-
logical replicates, error bars indicate stan-
dard deviations. Smears were stained using
DiffQuik staining set, parasitemia was
counted at 1000 RBCs. Statistical analysis
was performed in R using ANOVA
(Kolmogorov Smirnov test and the Bartlett
test passed): * = p < 0.05,
*** = p < 0.001 (compared to the DMSO
treated culture). Experimental conditions:
starting parasitemia 2% (dotted line),
medium with inhibitory compounds ex-
changed in 12 h intervals, total cultivation
duration 48 h. DC: DMSO treated culture
(0.008%). UC: untreated culture. IC50: half
maximal inhibitory concentration. RBCs:
red blood cells.
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untreated mice groups by the above described protocol. In addition,
Western blot analysis of poly-ubiquitinated proteins was performed
with the parasite lysates as described above.
2.11. Statistical analysis and graph design
Statistical analysis of B. divergens ex vivo culture treatment was
performed in R (version 3.2.2) using ANOVA (normal distribution
confirmed by Kolmogorov-Smirnov test, Bartlett test of homogeneity of
variances passed). IC50 was calculated and all graphs were designed in
GraphPad Prism software (version 5). The in vivo application of car-
filzomib was analysed in R using AUC (Area Under Curve), Cmax and
Tmax calculation. AUC was calculated using series of Reiman sums. The
AUC, Tmax and parasitemia values were compared using the two-sample
(independent) t-test (Kolmogorov-Smirnov test and the Bartlett test
passed). Data from cell toxicity and proteasome activity assays were
compared using the two-sample (independent) t-test (Kolmogorov-
Smirnov test and the Bartlett test passed). Mean values (± SD, standard
deviation) were counted from the biological triplicates (independent
experiments) and used for the graphical representations of the results
and their statistical analyses.
3. Results
3.1. Clinically approved proteasome inhibitors reduce B. divergens burden
in ex vivo cultures
Carfilzomib is a covalent and irreversible peptide epoxyketone in-
hibitor of the β5 subunit of the human proteasome and has been ap-
proved for clinical treatment of multiple myeloma. B. divergens infected
RBCs were treated with 6.25–400 nM of carfilzomib for 48 h and
parasitemia was quantified on thin blood smears (Fig. 1). Growth of B.
divergens was significantly inhibited by carfilzomib at 25 nM and above,
with an IC50 of 29 nM (Fig. 2A). In addition, B. divergens ex vivo cultures
were treated with two additional peptide epoxyketone inhibitors:
epoxomicin, a natural product isolated from actinomycetes, and ONX-
0914, a selective immunoproteasome inhibitor. Both inhibitors were
effective, but showed slightly lower potency than carfilzomib, with
epoxomicin and ONX-0914 having IC50 values 63 nM (Figs. 2B) and
100 nM (Fig. 2C), respectively. We next evaluated two covalent re-
versible peptide boronic acid inhibitors, bortezomib and ixazomib, in B.
divergens ex vivo cultures. Bortezomib significantly blocked parasite
replication at 50 nM concentration with an IC50= 47 nM (Fig. 3A)
while ixazomib treatment had no effect on parasite replication at
200 nM and reduced parasitemia by 64% at 400 nM (Fig. 3B).
3.2. Epoxyketone and boronic acid inhibitors reduce the chymotrypsin-like
activity of babesial proteasome
We anticipated that the proteasome inhibitors were targeting the β5
catalytic subunits of the B. divergens proteasome as they are known to
target the β5 subunit of mammalian proteasomes. To confirm this, we
prepared crude cellular lysates from B. divergens and used a standard β5
proteasome substrate, Suc-LLVY-AMC, to detect proteasome activity.
The lysate was pre-treated with 1 μM of E−64 to inhibit cysteine pro-
teases that can hydrolyse the Suc-LLVY-AMC substrate (Giguere and
Schnellmann, 2008). Pilot experimets consisting of the addition of 1 μM
of epoxyketone proteasome inhibitors carfilzomib, epoxomicin and
ONX-0914 to B. divergens cultures reduced Suc-LLVY-AMC measured
activity by>90% with carfilzomib treatment completely inhibiting
this activity. Similarly, 1 μM of the boronic acid inhibitors – bortezomib
and ixazomib – reduced the activity by 96.0% and 93.3%, respectively
(data not shown). The IC50 values of all five tested proteasome in-
hibitors obtained from the Suc-LLVY-AMC activity assays with B. di-
vergens crude cell lysates (Fig. 4A) correlate with the IC50 values of the
antiparasitic effects obtained from ex vivo B. divergens cultures
(Table 1) for all tested compounds except for ONX-0914. Taken to-
gether these results confirmed that the Suc-LLVY-AMC substrate can be
used to specifically monitor B. divergens proteasome proteolytic activity
from crude cell lysates and that the peptide-epoxyketone and peptide-
boronic acid inhibitors target the parasite proteasome. In order to fur-
ther confirm the on-target effect we immunoblotted parasite lysates
with antibodies that recognize the K48-linked ubiquitin to demonstrate
accumulation of poly-ubiquitinated proteins in B. divergens lysates fol-
lowing 12 h treatment of ex vivo cultures with 200 nM carfilzomib
(Supplementary Fig. 2). These data indicated that the cultured B. di-
vergens were unable to degrade poly-ubiquitinated proteins following
treatment with carfilzomib, thereby confirming that the parasite pro-
teasome was indeed inhibited by the drug. In mammalian cells, accu-
mulation of ubiquitinated proteins induces apoptosis and ultimately
cellular death (Demo et al., 2007; Khare et al., 2016); therefore ex-
posure of B. divergens to carfilzomib may also directly lead to cellular
death.
3.3. Carfilzomib is less toxic to immune host cells than to the parasite
With the exception of epoxomicin the proteasome inhibitors eval-
uated in this study were developed to target the human proteasome and
therefore we predicted that they would be more cytotoxic to human
cells than to B. divergens. To evaluate this, we assessed cytotoxicity of
these compounds with the proteasome inhibitor sensitive human cer-
vical cancer cell line, HeLa. Bortezomib and epoxomicin displayed IC50
values 7 nM and 4 nM making them significantly more cytotoxic to
mammalian cells compared to B. divergens, therefore ruling them out for
use in our rodent infection studies. Carfilzomib, ONX-0914 and ix-
azomib were 2–3.5-fold more potent against B. divergens compared to
HeLa. Out of these three compounds, carfilzomib had the highest po-
tency with IC50 of 59 nM and therefore we further investigated
Fig. 4. Detection and inhibition of B. divergens proteasome β5 subunit
activity. IC50 values of all tested proteasome inhibitors on B. divergens crude
cell lysates. Parasite lysates were obtained from ex vivo cultures and analysed
using the fluorogenic peptidyl substrate, Suc-LLVY-AMC. Results represent the
means of three independent replicates, error bars indicate standard deviations.
IC50 values were analysed using GraphPad Prism software (version 5).
Table 1
Summary of IC50 values for B. divergens and HeLa cells.
Proteasome
Inhibitor
IC50 values (nM)
B. divergens ex vivo
cultures
B. divergens activity
assay
HeLa cells
Carfilzomib 29 ± 10 2 ± 13 59 ± 36
Epoxomicin 63 ± 10 9 ± 5 4 ± 1
ONX-0914 101 ± 10 203 ± 7 350 ± 143
Bortezomib 47 ± 9 7 ± 14 7 ± 1
Ixazomib 350 ± 35 57 ± 14 810 ± 10
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carfilzomib cytotoxicity in a non-transformed mouse macrophage cell
line PMJ2R. Macrophages treated with 200 nM of carfilzomib, corre-
sponding to 2.5-times the B. divergens IC50 value, did not show any
toxicity. The survival rate of PMJ2R cells treated with carfilzomib
(71.1% ± 7.4) did not significantly differ from untreated cells
(67.8% ± 5.5) (Fig. 5). These data showed that B. divergens is more
sensitive to carfilzomib than non-transformed cells allowing us to
evaluate this drug in a rodent infection model for Babesia parasites.
3.4. Treatment of B. microti infected mice with carfilzomib displays
significant effects on the parasite
BALB/c mice intra-peritoneally infected with B. microti (Franca)
Reichenow (strain Peabody mjr) were treated daily from 1 DPI up to 7
DPI with 0.75mg/kg of carfilzomib. Growth curves counted as percent
parasitemia were generated from thin blood smears obtained by tail
snips. Treatment of infected mice with carfilzomib significantly reduced
peak parasitemia levels and the area under curve (AUC) compared to
PBS alone (Fig. 6A). Carfilzomib treatment had no adverse effects on
the spontaneous activity and physical appearance of mice. In addition,
treatment did not change the microscopic appearance of non-parasited
RBCs (data not shown). B. microti parasite cultures pre-treated with
400 nM carfilzomib for 1 h prior to mouse infection displayed a delayed
onset of parasitemia in mice (Fig. 6B). In addition, the Cmax value was
reduced by 31.2% on Tmax (= 7 DPI) when compared to the control
group. Longer exposure of B. microti infected erythrocytes to carfil-
zomib prior to mice infection was not possible as the untreated ex vivo
parasites were unable to efficiently infect the host when incubated for
longer than 1 h.
3.5. Carfilzomib reduces the chymotrypsin-like activity of B. microti
proteasome in vivo and results in accumulation of poly-ubiquitinated
proteins
Treatment of B. microti infected mice with 0.75mg/kg of carfil-
zomib only at 5 and 6 DPI (high parasitemia) resulted in decreased
parasite load in experimental mice from 47.4 ± 6.3% at 5 DPI to
41.5 ± 2.9% at 7 DPI as compared to control mice where parasitemia
gradually increased from 47.1 ± 4.6% to 58.8 ± 4.4%. Therefore, on
7 DPI there was a significant reduction in parasitemia (p= 0.0006)
upon treatment with carfilzomib. The B. microti crude cellular lysate
was prepared from mice blood collected at 7 DPI. The Suc-LVVY-AMC
activity assays showed a reduction by 33% (p= 0.0057) in carfilzomib
treated babesial lysates compared to the untreated control (Fig. 6C).
Immunoblot comparison of lysates confirmed accumulation of poly-
ubiquitinated proteins in B. microti originating from carfilzomib treated
mice using primary antibodies that recognize the K48-linked ubiquitin
(Fig. 6D). In both assays (Fig. 6C and D), equal amounts of parasite
proteins were used (visualized by coomassie stained SDS PAGE,
Fig. 6D). These results indicate that the in vivo exposure of B. microti to
carfilzomib results in significant decrease of parasite proteasome ac-
tivity followed by increased inability to degrade poly-ubiquitinated
proteins and, thus, confirms that B. microti proteasome is inhibited by
carfilzomib in the in vivo infected mouse model.
4. Discussion
In this study, we demonstrated that the proteasome of Babesia
parasites represents a novel therapeutic target. While genes encoding
proteasome subunits have been documented in the EST database of
Babesia bovis intra-erythrocytic stages (de Vries et al., 2006; Aboulaila
et al., 2010), the functional role of this enzyme complex in Babesia
species has yet not been characterised. Using a selection of peptide
boronic acid and peptide epoxyketone inhibitors we have confirmed
that the proteasome is enzymatically active in babesial protein extracts
and that this activity is important for ex vivo parasite growth. Although
babesiosis in humans is mostly asymptomatic the findings reported here
are of importance to both veterinary and human medicine especially
when antimalarial drugs and antibiotics have been reported to fail due
to suspected parasite drug resistance (Vial and Gorenflot, 2006; Vannier
et al., 2015).
Our cell-based assays and proteasome activity assays performed
with parasite lysates determined that all compounds reduce the chy-
motrypsin-like activity of babesial proteasome. Comparison of IC50
values identified carfilzomib, epoxomicin and bortezomib as the most
potent inhibitors however, the latter molecules were significantly more
cytotoxic towards the human cell line, HeLa (Supplementary Fig. 3).
These cells have been used extensively for evaluating drug toxicity and
have been shown to be sensitive to proteasome treatment (Gu et al.,
2014). Therefore, we evaluated potency of carfilzomib in a non-trans-
formed macrophage cell line and found that treatment with 200 nM did
not affect cell viability. These findings support previous studies with
non-transformed human fibroblast cells (HFF) that carfilzomib kills
with an IC50 of 492 nM (Li et al., 2012). Using this value, carfilzomib is
8.4-fold more selective for B. divergens cultures over HFF cells.
Bortezomib is known to inhibit several serine proteases, however,
the epoxyketone reactive group of carfilzomib exclusively targets the
active site threonine residue of proteasomes (Arastu-Kapur et al., 2011;
Kisselev et al., 2012). Carfilzomib, the FDA approved drug for treat-
ment of multiple myeloma in patients not responding to bortezomib
(Kuhn et al., 2007) was developed from the scaffold of epoxomicin, a
natural product of actinomycetes (Kim and Crews, 2013). Epoxomicin
has been previously shown to exhibit anti-babesial activity on intra-
erythrocytic multiplication of Babesia species B. bovis, B. bigemina, B.
Fig. 5. Cell viability assay: carfilzomib treatment
of macrophage cell line. (A) Results represent
means of three biological replicates for (i) carfil-
zomib (200 nM) and (ii) control (medium + 0.004%
DMSO) experiments; PMJ2R cells (medium changed
every 12 h, total cultivation 48 h). Error bars in-
dicate standard deviation. Statistical analysis was
performed in R using unpaired t-test (Kolmogorov-
Smirnov test and the Bartlett test passed). (B) Dot
plot results of flow cytometry analysis of carfilzomib
treated cells: dead cells (red color) stained by EthD
(measured in PE channel, emission 620 nm) and live
cells (green color) stained by Calcein (FITC channel,
emission 517 nm). DC: 0.004% DMSO treatment
control. EthD: ethidium homodimer. PE: phycoery-
thrin. FITC: fluorescein isothiocyanate. (For inter-
pretation of the references to color in this figure le-
gend, the reader is referred to the Web version of this
article.)
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ovata, B. caballi and B. microti with 3 day IC50 values ranging from 4 nM
to 40 nM (Aboulaila et al., 2010). Our studies with B. divergens identi-
fied carfilzomib as a more potent compound than epoxomicin while
also having lower mammalian cytotoxicity. Therefore carfilzomib was
selected for in vivo studies with B. microti infected mice.
Carfilzomib treatment of B. divergens in culture and B. microti in
mice results in the accumulation of endogenous poly-ubiquitinated
proteins within the parasite cell cytoplasm. These results further con-
firm that carfilzomib targets the parasite cell proteasome and indicate
that carfilzomib kills babesial infections by a mechanism relating to
proteasome inhibition known to cause cell death in mammals (Kuhn
et al., 2007).
B. microti was selected for in vivo studies because the rodent in-
fection model for B. divergens has not yet been described. Daily intra-
peritoneal treatment of Babesia-infected mice with carfilzomib resulted
in lower parasitemia on 5, 6 and 7 DPI compared to untreated control.
Under these conditions we did not observe any differences in animal
physical activity and red blood cell microscopic appearance between
the treated and untreated animal groups. Activity assays and Western
blots with B. microti lysates were performed to demonstrate that the
babesial proteasome is the target of carfilzomib in infected mice.
Animals were twice treated with carfilzomib at the peak of parasitemia
on 5 and 6 DPI only and blood was collected at 7 DPI to prepare B.
microti lysates originating from carfilzomib treated and untreated mice.
While in all the four untreated (control) infected mice the individually
counted parasitemia persisted or increased during 5, 6 and 7 DPI, in the
carfilzomib treated (experimental) mo use group it decreased in three
out of four individuals, when the one mouse without the decrease had a
significantly reduced (by 22%) initial parasitemia at 5 DPI
(Supplementary Table 1). The 33% decrease in Suc-LLVY-AMC activity
in B. microti lysates from pooled samples of carfilzomib treated mice
and the Western blot analysis demonstrating the accumulation of poly-
ubiquitinated proteins provide clear in vivo evidence of effective
parasite proteasome inhibition by carfilzomib in B. microti infected
mice.
To evaluate whether carfilzomib treatment completely eliminates
the parasite or if it only temporarily blocks its replication, we have
performed pre-treatment of B. microti infected erythrocytes with car-
filzomib prior peritoneal mice infection. Surprisingly, pre-treated
parasites were able to infect the host but with an obvious delay and
lowered parasitemia. We propose that the delay may be due to the
synthesis of new proteasome by the parasite as well as metabolic de-
gradation of carfilzomib in mice as this compound displayed high
plasma clearance (195–319ml/min/kg), a short-terminal half-life
(5–20min), and rapid and wide tissue distribution in rats (Yang et al.,
2011). It was previously shown that Babesia spp. parasites can grow
once the epoxomicin treatment is complete (Aboulaila et al., 2010).
This would only happen when parasites are treated with less than
50 nM of drug. Similarly, the low doses of carfilzomib temporarily ar-
rested the growth of Plasmodium spp. but higher dosing resulted in
parasite death (Li et al., 2012). Our ex vivo data with B. divergens er-
ythrocyte cultures display similar dose dependent effects when carfil-
zomib concentrations≥100 nM (Fig. 2A) result in parasitemia reduced
below the starting point of 2% indicating parasite killing by higher
compound concentrations.
While we have validated the Babesia proteasome as a target for drug
development, the toxicity associated with carfilzomib precludes it for
being used for treatment of babesiosis. Carfilzomib was also used to
validate the Plasmodium proteasome as a drug target (Li et al., 2012)
and subsequent studies have shown that compounds with 379-fold
Fig. 6. Treatment of B. microti infected mice. (A)
The growth curve of B. microti in mice treated with
either carfilzomib (0.75mg/kg) or PBS (control).
Treatment (intraperitoneal application) was per-
formed daily from 1 DPI up to 7 DPI (blue line in the
graph). (B) Growth curve of B. microti pre-treated
with either 400 nM carfilzomib for 1 h or vehicle
control prior to injection into mice. Respective va-
lues of AUC (Area Under Curve) and parasitemia
values were compared using the two-sample (in-
dependent) t-test; AUC and parasitemia values dif-
fered significantly: * = p < 0.05, ** = p < 0.01.
DPI: days post infection. (C) Inhibition of proteasome
chymotrypsin-like activity of B. microti isolated from
mice on 7 DPI. The infected animals were treated
with carfilzomib at 5 and 6 DPI. Activity was de-
tected in crude cell lysates using Suc-LLVY-AMC
fluorescent peptidyl substrate using equal amounts of
parasite proteins (visualized at coomassie gel,
Fig. 6D). Results represent the means of technical
triplicates, error bars indicate standard deviations.
Respective values were compared using the two
sample t-test: ** = p < 0.01. (D) Detection of poly-
ubiquitinated proteins in in vivo inhibited B. microti
proteasome on 7 DPI in B. microti crude cell lysate
obtained from mice previously treated on 5 and 6
DPI. Coomassie stained SDS PAGE visualizes sepa-
rated protein loads of treated and untreated parasite
lysates prior electro-blotting to PVDF membrane.
(For interpretation of the references to color in this
figure legend, the reader is referred to the Web ver-
sion of this article.)
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selectivity for the parasite can be developed (LaMonte et al., 2017).
Future studies will involve screening of compounds that selectively
inhibit the malarial proteasome for their ability to target Babesia spe-
cies. Substrate specificity characterization of the 20S catalytic subunits
of Babesia proteasome(s) will allow for rational design of peptide in-
hibitors that are selective for the parasite proteasome over the mam-
malian host constitutive proteasome and immunoproteasome. Also
detailed structure studies using cryoEM (Li et al., 2016a) may uncover
differences between the catalytic subunits of the babesial 20S protea-
some and the mammalian proteasomes to that can be used to design
novel selective inhibitors of the Babesia proteasome on the way to de-
termine highly selective therapeutic compounds.
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